Lyell Immunopharma (Nasdaq:LYELL) has reported initial clinical and translational data from its Phase 1 trial of LYL797, a first-generation reprogrammed ROR1 CAR T cell product candidate enhanced with proprietary anti-exhaustion technology with potential use in triple negative breast cancer (TNBC).
The company announced clinical findings demonstrating that LYL797 ROR-1-targeted CAR T cells exhibited dose-dependent antitumor clinical activity and have the potential to deliver meaningful benefits to TNBC patients through continued dose escalation.
The study includes a robust translational program, with the company reporting the first demonstration that CAR T cells enhanced with anti-exhaustion technology expanded, persisted, and infiltrated into solid tumors, showing some associated evidence of cancer cell killing.
In a statement, Lynn Seeley, M.D., president and CEO of Lyell, said, “This early validation of our anti-exhaustion technology gives us the conviction to expand our trial to include patients with ROR1+ ovarian or endometrial cancers, while continuing to enroll patients with TNBC or non-small cell lung cancer, and also to initiate new clinical trial for patients with multiple myeloma and chronic lymphocytic leukemia.”
